Lucerna Inc.
Los Angeles, CA
- UEI
- J3MWGA6WFCG3
- CAGE
- 5XRS8
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 5413 W 76th St #327c, Westchester, CA 90045, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| In vivo imaging platform for DM1 drug discovery - project abstract/summary myotonic dystrophy type 1 (DM1) is a… | National Insititue of Arthritis and Musculoskeletal and Skin Diseases | $626,296 | |
| Targeted RNA degradation assay for new antiviral drug discovery - project summary there are currently no effective… | National Institute of Allergy and Infectious Diseases | $300,000 | |
| Cell-based RNA degradation assay for C9ALS/FTD drug discovery - project summary to overcome the "undruggable" protein… | National Institute on Aging | $392,116 | |
| Fluorescent IRE sensor for synucleinopathy drug discovery - abstract the goal of this phase II proposal is to advance… | National Institute of Neurological Disorders and Stroke | $5,184,693 | |
| Cell-based assay directly monitoring RNA polymerase i activity for cancer drug discovery | National Cancer Institute | $223,700 |
About Lucerna Inc.
Lucerna Inc. is a minority-owned and woman-owned small business corporate entity registered in SAM.gov since 2010, focusing on advanced biomedical research and development of innovative technological platforms for drug discovery. The company specializes in developing cutting-edge RNA-based technologies and diagnostic tools that enable more efficient screening and evaluation of potential therapeutic interventions across various disease domains. With a strong emphasis on proprietary fluorogenic RNA aptamer technology, Lucerna Inc. appears to leverage advanced molecular engineering techniques to create novel in vivo imaging and screening platforms that can transform preclinical research methodologies.
The company has secured multiple federal grants from prestigious national institutes, including the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Allergy and Infectious Diseases, and National Institute on Aging. Lucerna's grant-funded projects concentrate on developing high-throughput screening assays and innovative diagnostic technologies for challenging medical conditions such as myotonic dystrophy type 1 (DM1), viral diseases like dengue and influenza, neurodegenerative disorders including amyotrophic lateral sclerosis (ALS), frontotemporal dementia, and synucleinopathies. Their research primarily focuses on creating advanced cell-based RNA degradation assays, targeted RNA detection platforms, and non-invasive imaging technologies that can monitor RNA dynamics, toxic protein aggregation, and potential drug interactions at the molecular level. These projects aim to overcome current limitations in drug discovery by providing more efficient, precise, and adaptable screening methodologies that could potentially accelerate therapeutic development across multiple complex disease domains.
Quick answers
What is Lucerna Inc.'s UEI?
Lucerna Inc.'s Unique Entity ID (UEI) in SAM.gov is J3MWGA6WFCG3.
What is Lucerna Inc.'s CAGE code?
Lucerna Inc.'s CAGE code is 5XRS8.
What is Lucerna Inc.'s primary NAICS code?
Lucerna Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Lucerna Inc. located?
Lucerna Inc.'s physical address in SAM.gov is 5413 W 76th St #327c, Westchester, CA 90045, USA.
Is Lucerna Inc. registered in SAM.gov?
Yes. Lucerna Inc.'s SAM.gov registration is active through June 15, 2027.
What is Lucerna Inc.'s most recent federal award?
Lucerna Inc.'s most recent federal grant award is In vivo imaging platform for DM1 drug discovery - project abstract/summary myotonic dystrophy type 1 (DM1) is a… (R43AR086092), from National Insititue of Arthritis and Musculoskeletal and Skin Diseases, on August 1, 2025.
On GovTribe
See Lucerna Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors